---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Base case"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Base case. Topics: Base-case budget impact of nadofaragene firadenovec in a plan of one million members, Potential budget impact of nadofaragene firadenovec in the ICER review, Base-case cost-effectiveness of radical cystectomy and bladder-sparing treatments over 5 years, Base-case cost per responder of TAR-200 versus FDA-approved comparators, and 2 further topics. 6 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics/base-case"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Base case

<a id="heading-4.2.6.1"></a>

## 4.2.6.1 Base Case

<a id="topic-4.2.6.1-1"></a>

### Budget impact model of cretostimogene grenadenorepvec: base-case results

No evidence found.

<a id="topic-4.2.6.1-2"></a>

### Base-case budget impact of nadofaragene firadenovec in a plan of one million members

> “On a plan total basis, the budget during Years 1, 2, and 3 were $358,037, $487,675, and $564,877, respectively, under the scenario without nadofaragene firadenovec entry versus $369,997, $523,127, and $665,977 under the scenario with nadofaragene firadenovec entry, corresponding to a budget impact of $11,960, $35,452, and $101,099”
> “On a per-member-per-month (PMPM) basis, the budgets from Years 1 − 3 were $0.0298, $0.0406, and $0.0471, respectively, under the scenario without nadofaragene firadenovec entry versus $0.0308, $0.0436, and $0.0555 under the scenario with nadofaragene firadenovec entry, corresponding to a budget impact of $0.0010, $0.0030, and $0.0084 PMPM”
> “Increased drug and administration costs were partially offset by cost savings from reduced disease progression, fewer cystectomies, and lower AE rates.”

Source: [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599)

<a id="topic-4.2.6.1-3"></a>

### Potential budget impact of nadofaragene firadenovec in the ICER review

> “The average potential budgetary impact for nadofaragene firadenovec was an additional per-patient cost of approximately $128,000 in year one, with net annual savings in following years leading to cumulative costs per patient of approximately $98,000 by year five.”
> “As shown in Figure 8.2, approximately 52% of eligible patients could be treated in a given year without crossing the ICER budget impact threshold of $819 million at the assumed placeholder price.”

Source: [ICER Bladder Cancer Final Evidence Report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_Bladder_Cancer_Final_Report_07292022.pdf)

<a id="topic-4.2.6.1-4"></a>

### Base-case cost-effectiveness of radical cystectomy and bladder-sparing treatments over 5 years

| Index patient and strategy | Cost (5-year USD) | Effectiveness (5-year QALY) | ICER (USD/QALY) | Net monetary benefit |
| --- | --- | --- | --- | --- |
| Index patient 1: gemcitabine/docetaxel | “78,539” | “3.95” | “Ref.” | “316,053” |
| Index patient 1: radical cystectomy | “96,909” | “3.78” | “−109.912” | “280,971” |
| Index patient 1: pembrolizumab | “226,879” | “3.82” | “−1,137,869” | “154,677” |
| Index patient 1: nadofaragene | “296,318” | “3.84” | “−2,154,264” | “88,165” |
| Index patient 1: NAI-BCG | “529,801” | “3.85” | “−4,685,203” | “−144,840” |
| Index patient 3: pembrolizumab | “419,022” | “3.88” | “Ref.” | “−31,083” |
| Index patient 3: nadofaragene | “449,307” | “3.90” | “1,469,775” | “−59,307” |
| Index patient 3: NAI-BCG | “704,172” | “3.83” | “−3,847,835” | “−320.796” |

Source: [Myers et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13454959/)

<a id="topic-4.2.6.1-5"></a>

### Base-case cost per responder of TAR-200 versus FDA-approved comparators

> “The TAR-200 cohort demonstrated the lowest total cost per patient achieving and sustaining CR for ≥12 months, with an estimated cost of $1,892,569 when NAI+BCG reinduction was not considered.”
> “In comparison with the other treatment cohorts, TAR-200 was associated with meaningful cost savings per patient achieving and sustaining CR for ≥12 months, including $698,262 relative to pembrolizumab, $406,840 relative to NF, $832,346 relative to NAI+BCG, and $1,541,999 relative to valrubicin.”

Source: [Williams et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2651037)

<a id="topic-4.2.6.1-6"></a>

### Base-case incremental cost-effectiveness ratios in the ICER review, CIS ± Ta/T1

| Intervention | Cost per QALY gained | Cost per evLYG | Cost per year in progression-free state |
| --- | --- | --- | --- |
| Nadofaragene firadenovec | “$151,000” | “$135,000” | “$100,000” |
| Oportuzumab monatox | “$382,000” | “$343,000” | “$281,000” |
| Pembrolizumab | “$114,000” | “$103,000” | “$76,000” |

Source: [Beinfeld et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391138/)

<a id="topic-4.2.6.1-7"></a>

### Manufacturer-reported cost-consequence results for nogapendekin alfa inbakicept plus BCG versus TAR-200

> “Cost per cystectomy avoided: ANKTIVA plus BCG demonstrated savings of $109,622 at Year 1, $151,438 at Year 2, and $60,393 at Year 3 compared to TAR-200”
> “Cost per complete responder: Savings of $313,775 at Year 1 and $282,013 at Year 2”
> “Cost reductions were primarily driven by lower drug acquisition and administration costs, based on complete response rates derived from an indirect treatment comparison”
> “49.6% for ANKTIVA plus BCG versus 45.9% for TAR-200.”

Source: [ImmunityBio ISPOR 2026 health economic analysis press release (2026)](https://immunitybio.gcs-web.com/node/11506)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
